Genzyme gets EU nod for Aubagio; NICE OKs Novartis' Jetrea; Study finds therapeutic drug subbing saves money;

@FiercePharma: Bayer's new cancer drug Stivarga (with Onyx) wins approval in Europe, for metastatic colorectal. Release | Follow @FiercePharma

@EricPFierce: J&J takes another step to warn consumers that if you take too much acetaminophen, it will kill you. Story | Follow @EricPFierce

@CarlyHFierce: Cubist recalls four lots of antibiotic Cubicin because of glass particles. More from FiercePharmaManufacturing | Follow @CarlyHFierce

> Sanofi's ($SNY) Genzyme said the European Commission has approved Aubagio, its once-daily pill for treating adults with relapsing remitting multiple sclerosis. Release

> The National Institute for Health and Care Excellence (NICE) has recommended Novartis' ($NVS) Jetrea in the U.K. for treatment of a rare eye condition called vitreomacular traction. Story

> A study found that therapeutic drug substitutions, using less expensive substitutes that are not equivalent but have a similar treatment effect as the original medication, could save payers about three times more than generics. Story

> An FDA official in India says the agency is not specifically targeting Indian companies for enforcement. Story

Medical Device News

@FierceMedDev: Meda grabs MA maker of asthma inhaler for $135M. Story | Follow @FierceMedDev

@MarkHFierce: Covidien won yet another patent battle with a rival. Patent spats aren't cheap. News | Follow @MarkHFierce

@MichaelGFierce: European public health group gets behind tighter device controls. Item | Follow @MichaelGFierce

> Texas neurostim startup pulls in $3.4M for multiple trials. Article

> Medtronic looks to innovate with new Singapore shop. More

> Covidien claims victory in surgical tool patent dustup. Story

Biotech News

@FierceBiotech: Report: Big CROs soared 10% last year. More from FierceCRO | Follow @FierceBiotech

@RyanMFierce: Icon Bioscience snags $15M in B round for eye therapies. News | Follow @RyanMFierce

@EmilyMFierce: ICYMI: UM Pharmacy School researchers develop new opioid pain drug that decreases tolerance, side effects. Article | Follow @EmilyMFierce

> Report: Clarus, OrbiMed pioneer paths to biotech VC victories. Story

> Meda to scoop up Sequoia-backed pharma startup Acton for $135M. Report

> Johnson & Johnson inks R&D pact to fight growing threat of dengue infections. More

And Finally... A design award has gone to Kanupriya Goel and biologist Gautam Goel for a drug label that reacts over time to reveal a hidden message that the drug is expired. Story

 

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.